EVEREST MED (01952) announced its annual results for the period ending December 31, 2025. The group recorded revenue of RMB 1.707 billion, representing a year-on-year increase of 141.51%. The loss attributable to shareholders was RMB 298 million, while research and development expenses totaled RMB 511 million. Gross profit reached RMB 1.182 billion, up 124.32% compared to the previous year.

The significant revenue growth was primarily driven by increased sales of Nefecon® in commercialized markets. In China, the inclusion of Nefecon® in the National Reimbursement Drug List (NRDL) served as a key growth driver, contributing substantially to the product's revenue for the fiscal year. In markets outside mainland China, Nefecon® achieved successful launches and important milestones in Taiwan and South Korea, with sales continuing to rise in other Asian markets.

Additionally, VELSIPITY® was successfully launched in the Singapore market. These accomplishments highlight the group's progress in expanding its presence across Asia and improving patient access to medications.

During the year, the company successfully achieved multiple R&D milestones and has been actively optimizing its research strategy to accelerate the development of its in vivo CAR-T and mRNA platforms. These efforts are advancing toward next-stage research and clinical readiness while further unlocking the value of EVER001 (Xibutinib).

Leveraging its strong clinical development capabilities, the company has also enriched its late-stage product pipeline through strategic collaborations and licensing agreements.